Molecular Cytogenetic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Global Molecular Cytogenetic Market was valued at USD 469.2 million in 2013 and is estimated to reach a market worth USD 1.97 billion in 2019 at a CAGR of 23.4% from 2013 to 2019.

Browse the full report at http://www.transparencymarketresearch.com/molecular-diagnostics-market.html

Molecular cytogenetics is emerging as an indispensable tool in the field of research and diagnosis. Until the advent of molecular cytogenetics techniques in 1980s, chromosomal analysis was mainly based on banding patterns. Although, the traditional banding techniques encountered problems such as low resolution and poor quality analysis. However, breakthrough in fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization (aCGH) techniques has enhanced the diagnosis of chromosomal anomalies particularly in tumor and hematological malignancies. Nowadays, cytogenetics techniques are being considered mandatory in diagnosis and prognosis of leukemia. The techniques are considered as a standard laboratory test since they provide global screening of abnormalities. The scope of molecular cytogenetics is increasing with the rising cancer incidences worldwide and growing popularity of personalized medicines.
The ability of FISH technique to study cells at an interphase stage of the cell cycle has made the technique a breakthrough in molecular cytogenetics field. FISH technique is used in the research of diverse applications such as cancer, cardiovascular and genetic disorder. The impetus of FISH technique is a direct result of improved understanding of sequence, structure and function of human genome. Similarly, supported by technological advancements in fluorescent microscopes and digital imaging, FISH technique has emerged as a preferred tool in molecular cytogenetics. The technique facilitates the analysis of sub-chromosomal regions and the identifications of small translocations thereby, routinely used in clinical applications. Owing to the techniques' sensitivity and specificity, FISH is significantly used in number of cytogenetic and pathological laboratories.

The advent of aCGH is ushering new standards for the analysis of genome. The technology has turned out to be a greatest driver for the molecular cytogenetics market as it is overcoming the resolution problems associated with traditional banding techniques. aCGH is poised to witness a significant growth in the market and is likely to emerge as the fastest growing technology segment. aCGH has propelled the cytogenetics market from the microscopes to computers and thus, facilitated simultaneous analysis of thousands of discrete regions of the genome. Similarly, the technique is gaining popularity as one assay performed on this technique is comparable to thousands of FISH experiments and hence, saves time and cost. Moreover, the technique is expected to rapidly supplant FISH technique owing to further technological advancements in the technique. Likewise, increasing sensitivity of the aCGH technique is preferred as a primary diagnosis tool followed by validation with FISH. The technique is emerging as a powerful tool for high resolution analysis of sub-microscopic chromosomal abnormalities. aCGH is also evolving as a method of choice for molecular cytogenetics by the researchers owing to its work flow advantages and cost effectiveness.
North America accounts for the largest share of the molecular cytogenetics market followed by the European region. The markets for these regions are driven by factors such as increased level of public awareness, rising cancer incidences and large number of research institutes engaged in cytogenetics field. However, Asia-Pacific region is likely to emerge as the fastest growing region over the analysis period. Cancer diagnosis is likely to witness a significant growth and emerge as the fastest growing segment during analysis period with a CAGR of more than 20%.

The growing demand for molecular cytogenetics techniques in research and data interpretation has resulted in quick expansion of manufacturers' product portfolio. The manufacturers are focused on building aggressive strategies for the development of innovative products that would cater research and diagnostic sectors. The vendors are eager to tap the emerging regions and end-users of this market. Major players engaged in development of innovative molecular cytogenetics techniques are Abbott laboratories, Affymetrix, Inc., Applies Spectral Imaging, BI Biological Industries, Life Technologies Corporation, Roche Diagnostics, Oxford Gene Technology, Illumina, Inc., among others.  
The molecular cytogenetics market is segmented as follows:

·         Molecular Cytogenetics Market, by Technology

FISH
aCGH

·         Molecular Cytogenetics Market, by Application

Genetic Disorders
Cancer
Personalized Medicine
Others

·         Molecular Cytogenetics Market, by Geography

North America
Europe
Asia-Pacific
RoW


 http://www.transparencymarketresearch.com/molecular-diagnostics-market.html 


About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Visit: http://de.transparencymarketresearch.com/
Visit: http://www.europlat.org/

Fuel Cells Market is growing at a CAGR of 13.0% from 2013 to 2019.By Transparency Market Research

Transparency Market Research Report Add Fuel Cells Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019," to its database.

            The Fuel Cells Market was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from 2013 to 2019 to reach an estimated value of USD 2,937.3 million by 2019.

                Browse the full report at http://www.transparencymarketresearch.com/fuel-cell-market.html

This report analyzes and estimates the demand for fuel cells in the global scenario. The fuel cell market is segmented on the basis of application, type, fuel and geography. Regional and product-based market data is given in terms of both volumes and revenues for the period from 2010 to 2018.

Various fuel cell products analyzed in this study include direct methanol fuel cell (DMFC), proton exchange membrane fuel cell (PEMFC), molten carbonate fuel cell (MCFC), alkaline fuel cell (AFC), phosphoric acid fuel cell (PAFC) and solid oxide fuel cell (SOFC).

The fuel cells market by applications is majorly divided into stationary, transportation and portable. The economies covered in this report are Asia-Pacific, Europe, North America, and Rest of the World (ROW). Regional data has also been provided for key countries such as U.S., Canada, Japan, South Korea, Germany, UK, Norway, Denmark and Sweden. The fuel cells market by various fuels such as hydrogen, natural gas and methane has also been analyzed in this report along with type, application and geography.

This report also includes market share of major companies in 2011, value chain analysis and porters five forces model. Some of the key players profiled in this study include Fuel Cell Energy, Ballard, Clearedge, Toshiba, Panasonic, Plug Power Inc. and Hydrogenics Corporation. The report gives a brief overview of the major companies that are dealing in fuel cells followed by their business strategies, financial revenue and recent developments.

This research has been specially conducted to estimate and analyze the performance and demand of fuel cells in a global scenario. The research provides detailed analysis of companies that are dealing in fuel cells, trend analysis of fuel cells market and demand by geography. The report includes all the major types and application segments of the fuel cells market and provides statistically refined forecast and historical data for the segments covered. The report presents a comprehensive assessment of the strategies followed by different stakeholders by segmenting the fuel cells market as below:

Global Fuel Cells market, by fuel

• Hydrogen
• Natural Gas
• Methanol

Global Fuel Cells market, by type

• Proton Exchange Membrane Fuel Cell (PEMFC)
• Direct Methanol Fuel Cell (DMFC)
• Phosphoric Acid Fuel Cell (PAFC)
• Solid Oxide Fuel Cell (SOFC)
• Molten Carbonate Fuel Cell (MCFC)
• Alkaline Fuel Cell (AFC)

Global Fuel Cells market, by application

• Stationary
• Transportation
• Portable

Global Fuel Cells market, by geography

• North America
• U.S.
• Canada

• Europe
• Germany
• U.K.
• Denmark
• Norway
• Sweden

• Asia-Pacific
• Japan
• South Korea

Liver Diseases Therapeutics Market is growing at a CAGR of 13.0% from 2013 to 2019.By Transparency Market Research.

The Liver Diseases Therapeutics Market  was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from 2013 to 2019 to reach an estimated value of USD 2,937.3 million by 2019.

        Browse the full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html 
           The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side-effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.
           Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future.
         The major players in the liver diseases therapeutics market include Astellas Pharma Inc, Gilead Science Inc, Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. In 2011, Astellas was the market leader in the immunosuppressants drugs market for liver diseases followed by Pfizer. In liver disease vaccines market, GlaxoSmithKline Pharmaceuticals Limited (GSK) represented as the major market player with a share of 45% in 2011. Bristol Myers Squibb had the largest market share in anti-viral drugs market for liver diseases followed by Gilead science in 2011.
     This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.

Molecular Cytogenetics Market (Technologies: FISH and aCGH; Applications: Genetic Disorders, Cancer and Personalized Medicine) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Molecular cytogenetics is emerging as an indispensable tool in the field of research and diagnosis. Until the advent of molecular cytogenetics techniques in 1980s, chromosomal analysis was mainly based on banding patterns. Although, the traditional banding techniques encountered problems such as low resolution and poor quality analysis.


Browse the full report at http://www.transparencymarketresearch.com/molecular-diagnostics-market.html

 However, breakthrough in fluorescence in situ hybridization (FISH) and array-comparative genomic hybridization (aCGH) techniques has enhanced the diagnosis of chromosomal anomalies particularly in tumor and hematological malignancies. Nowadays, cytogenetics techniques are being considered mandatory in diagnosis and prognosis of leukemia.


 The techniques are considered as a standard laboratory test since they provide global screening of abnormalities. The scope of molecular cytogenetics is increasing with the rising cancer incidences worldwide and growing popularity of personalized medicines.

The ability of FISH technique to study cells at an interphase stage of the cell cycle has made the technique a breakthrough in molecular cytogenetics field. FISH technique is used in the research of diverse applications such as cancer, cardiovascular and genetic disorder. The impetus of FISH technique is a direct result of improved understanding of sequence, structure and function of human genome. Similarly, supported by technological advancements in fluorescent microscopes and digital imaging, FISH technique has emerged as a preferred tool in molecular cytogenetics. 


The technique facilitates the analysis of sub-chromosomal regions and the identifications of small translocations thereby, routinely used in clinical applications. Owing to the techniques' sensitivity and specificity, FISH is significantly used in number of cytogenetic and pathological laboratories.


The advent of aCGH is ushering new standards for the analysis of genome. The technology has turned out to be a greatest driver for the molecular cytogenetics market as it is overcoming the resolution problems associated with traditional banding techniques. aCGH is poised to witness a significant growth in the market and is likely to emerge as the fastest growing technology segment. aCGH has propelled the cytogenetics market from the microscopes to computers and thus, facilitated simultaneous analysis of thousands of discrete regions of the genome.


 Similarly, the technique is gaining popularity as one assay performed on this technique is comparable to thousands of FISH experiments and hence, saves time and cost. Moreover, the technique is expected to rapidly supplant FISH technique owing to further technological advancements in the technique. Likewise, increasing sensitivity of the aCGH technique is preferred as a primary diagnosis tool followed by validation with FISH. The technique is emerging as a powerful tool for high resolution analysis of sub-microscopic chromosomal abnormalities. aCGH is also evolving as a method of choice for molecular cytogenetics by the researchers owing to its work flow advantages and cost effectiveness.

Global Epigenetic Drugs and Diagnostic Technologies Market growing at a CAGR of 19.4% from 2013 to 2019. By Transparency Market Research

The growth of the epigenetic market is driven by factors such as increase in aging population, as there is a strong correlation between cancer and aging. According to WHO, it is estimated that global population over the age of 60 years would double from 11% (2000) to 22% (2050). People aged 60 and above are more prone to cancer. Hence, countries are advocating early detection of cancer through screening kits (Epi Procolon, Epi ProLung) which are driving the epigenetic drugs and diagnostic technologies market.

Browse the full report at  http://www.transparencymarketresearch.com/epigenetics-market.html

Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states. The inhibitors, DNA methyltransferase (DNMT) and Histone Deacetylase (HDAC) are responsible for regulating the cellular expression. Out of the two inhibitors, DNMT accounts for a larger share as these inhibitors offer an improved access for targeting the cancerous cells. Currently, four drugs are approved by FDA and are commercially available. 

Two of them are DNMT inhibitors: Celgene's Vidaza (azacitidine) and Eisai's Dacogen (decitabine) for the treatment of Myelodysplastic Syndrome (MDS), and the other two are HDAC inhibitors: Merck's Zolinza (vorinostat) and Celgene's Istodax (romidepsin) both for treatment of Cutaneous T Cell Lymphoma (CTCL).

Epigenetics is a rapidly developing field not only in oncology but also in non-oncology indications (Alzheimer's and arthritis). Due to the increase in disease identification, manufacturers are taking initiatives in development of varied epigenetic diagnostic techniques. DNA methylation technique in the diagnostic segment accounts for the largest share as compared to histone modification techniques, as the research on DNA methylation has been carried out since decades, and is thus mostly preferred. Furthermore, with the corresponding advancements in research and technology, histone code hypothesis technique came into existence only in late 1980s. Hence, with the surge in interest, there is also an increase in investment for the research and development of histone modifications.

North America accounts for the largest share of the epigenetics market. It is expected that North Americawill dominate around half of the global epigenetics market due to increasing incidence of cancer and other non-oncology indications. Oncology and other non-oncology indications (Alzheimer's and arthritis) are associated with epigenetics; thus the increasing incidence of cancer supports the growth of the epigenetics market. 

Asia accounts for nearly half of the new cancer cases worldwide. The rising incidence of cancer cases in the Asian region would boost the demand for epigenetic drugs and diagnostic technologies in this market. 

Australia, China, Japan and South Korea are the largest markets for these herapies. Japan dominates the epigenetics market in Asia-Pacific due to a significant presence of companies in the therapeutics segment such as Eisai Pharmaceuticals and Oncolys Biopharma. These companies are taking initiatives for the development and commercialization of epigenetic drugs. Various research institutes and investments from these companies would drive the epigenetics market.

Some of the key players in this market include Celgene Corporation, Merck, Eisai Pharmaceuticals, Exact Sciences, Epigenomics and others. Manufacturers are entering into strategic alliances with numerous research institutions and other players for the development and commercialization of new and innovative drugs, which might see new players in the market looking to carve out a share of the market for themselves.